Life Science Investing Bristol Myers Squibb Builds on Eliquis® Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu®
Life Science Investing Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma
Life Science Investing Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025
Life Science Investing Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
AFDG - Embracing US strategy, acquisition of Butembo copper deposit in the DRC. Copper added to draft list of US strategic minerals
Fortune Minerals Announces David Massola Has Rejoined the Company as Vice President Business Development
